Clinical Trials Logo

Filter by:
NCT ID: NCT02752074 Completed - Melanoma Clinical Trials

A Phase 3 Study of Pembrolizumab + Epacadostat or Placebo in Subjects With Unresectable or Metastatic Melanoma (Keynote-252 / ECHO-301)

Start date: June 21, 2016
Phase: Phase 3
Study type: Interventional

The purpose of the study is to assess the efficacy, safety, and tolerability when combining pembrolizumab with epacadostat or placebo in participants with unresectable or metastatic melanoma

NCT ID: NCT02751931 Completed - Clinical trials for Neurogenic Detrusor Overactivity

Open-label Phase 3 Study With Mirabegron in Children From 3 to Less Than 18 Years of Age With Neurogenic Detrusor Overactivity

Crocodile
Start date: June 17, 2016
Phase: Phase 3
Study type: Interventional

The objective of the study was to evaluate the efficacy, safety, tolerability and pharmacokinetics of mirabegron after multiple-dose administration in the pediatric population.

NCT ID: NCT02751879 Completed - Clinical trials for Carcinoma, Non-Small-Cell Lung

Real World Data on Gi(l)Otrif® Dose Adjustment

Start date: November 24, 2016
Phase:
Study type: Observational

This is a non-interventional, multi-country, multi-site study based on existing data from medical records of patients treated with Gi(l)otrif® as part of the routine treatment according to the approved label. Data from real-world will help to understand if dose modifications are done similar as in LUX-Lung 3 trial and if the outcome on safety and effectiveness are as in trial settings. Furthermore, data on modified starting doses, the underlying reasons and effects on safety and outcome are needed.

NCT ID: NCT02749357 Completed - Clinical trials for Spinal Cord Injuries

Robotic Gait Training in Spinal Cord Injury

Start date: May 2016
Phase: N/A
Study type: Interventional

INTRODUCTION: The ability to move and transfer own body in an effective manner, is frequently affected in people with a spinal cord injury with a negative impact in mood and quality of life, in such a way, that achieving an effective locomotion, is one of the main objectives in the rehabilitation program in a spinal cord injured patient. There are different modalities of locomotion training in spinal cord injury, being the robotic orthosis among them, and offering until now, positive outcomes. However there´s still a lack of evidence of the optimal training characteristics, in order to establish the best time, number of sessions, and progression scheme. For these reasons, establishing the effects of different locomotion training programs will provide the necessary data in order to develop an effective training program for the maximum benefit of the patient. OBJECTIVE To determine the effect of different training programs with robotic gait orthosis for patients with chronic motor incomplete spinal cord injury (SCI) (American Spinal Injury Association Impairment Scale (AIS) C / D) in short and long term. METHODS AND DESIGN. The design of the study consists on a randomized, blinded to the observer, clinical trial. Patients from the National Institute of Rehabilitation (INR) with spinal cord injury, AIS C and D, with at least 6 months of evolution, and who are able to walk with or without gait auxiliary, will be eligible. Informed consent will be obtained from all subjects prior to participation. Patients will be randomly assigned to either one of the two different training groups: intervention or control group. The control group will be submitted to training sessions of 30 minutes, and the intervention group will have training sessions of 60 minutes. Both groups will receive a training period of six weeks, five days a week. Throughout the training period, gait assessments with the GaitRite instrument, will be performed, and repeated at 6 and 12 months after completion of the training as part of follow up. The data obtained from the GaitRite will be compared within each group, in order to determine which type of training is more effective Statistical analysis will be performed using SPSS, considering all P < 0.05 as statistically significant.

NCT ID: NCT02747043 Completed - Clinical trials for Lymphoma, Non-Hodgkin

Study to Assess if ABP798 is Safe & Effective in Treating Non Hodgkin Lymphoma Compared to Rituximab

JASMINE
Start date: May 25, 2016
Phase: Phase 3
Study type: Interventional

This was a randomized, double-blind, active-controlled, multiple-dose, clinical similarity study to evaluate the efficacy, pharmacokinetics, pharmacodynamics, safety, tolerability and immunogenicity of ABP 798 compared with rituximab in subjects with grade 1, 2, or 3a follicular B-cell NHL and low tumor burden. Subjects were randomized in a 1:1 ratio to receive a 375 mg/m^2 intravenous infusion of either ABP 798 or rituximab once weekly for 4 weeks followed by dosing at weeks 12 and 20.

NCT ID: NCT02747004 Active, not recruiting - Clinical trials for Metastatic Breast Cancer

A Study of Abemaciclib (LY2835219) Plus Tamoxifen or Abemaciclib Alone in Women With Metastatic Breast Cancer

Next MONARCH 1
Start date: September 14, 2016
Phase: Phase 2
Study type: Interventional

The main purpose of this study is to evaluate the safety and efficacy of abemaciclib plus tamoxifen or abemaciclib alone in women with previously treated hormone receptor-positive (HR+), human epidermal growth factor receptor 2 negative (HER2-), metastatic breast cancer.

NCT ID: NCT02745093 Not yet recruiting - Medical Abortion Clinical Trials

Medical Abortion at Gestational Age of 8 to ≤9 Weeks Versus >9 to ≤12 Weeks

Start date: September 2016
Phase: Phase 4
Study type: Interventional

The purpose of this study is to assess the effectiveness, safety, and acceptability of home-administered medical abortion at gestational age of 8 to ≤9 weeks versus >9 to ≤12 weeks among a cohort of women in Mexico City.

NCT ID: NCT02744755 Completed - Clinical trials for Rheumatoid Arthritis

Clinical Trial to Compare Treatment With GP2017 and Humira® in Patients With Rheumatoid Arthritis

ADMYRA
Start date: March 31, 2016
Phase: Phase 3
Study type: Interventional

Clinical trial to compare treatment with GP2017 and Humira® in patients with Rheumatoid Arthritis

NCT ID: NCT02743494 Active, not recruiting - Advanced Cancer Clinical Trials

An Investigational Immuno-therapy Study of Nivolumab or Placebo in Participants With Resected Esophageal or Gastroesophageal Junction Cancer

CheckMate 577
Start date: July 14, 2016
Phase: Phase 3
Study type: Interventional

The primary purpose of this study is to determine whether Nivolumab will improve disease-free survival compared with placebo.

NCT ID: NCT02741570 Completed - Clinical trials for Head and Neck Cancer

Study of Nivolumab in Combination With Ipilimumab Compared to the Standard of Care (Extreme Regimen) as First Line Treatment in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

CheckMate 651
Start date: October 5, 2016
Phase: Phase 3
Study type: Interventional

The main purpose of this study is to compare nivolumab and ipilimumab with the extreme regimen as first line treatment in patients with recurrent or metastatic squamous cell of the head and neck cancer